Publications
5674 Results
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr TPS5102);ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
- Year
- 2014
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216
SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy (ADT) + TAK-700 with ADT + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (HSPC) (NCT01809691)
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr 6022); ASCO (May 30-June 3, 2014, Chicago, IL), poster highlights session;
- Year
- 2014
- Research Committee(s)
- Head and Neck
- Study Number(s)
- SWOG-8892 (INT-0099) (EST-2388) (RTOG-8817)
Meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 4,798 patients
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr 506); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), oral session;
- Year
- 2014
- Research Committee(s)
- Breast
Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa)
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr LBA3); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), scientific plenary session (oral);
- Year
- 2014
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (uMCRC).
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr 6617); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
- Year
- 2014
- Research Committee(s)
- Leukemia
- Study Number(s)
- S1117
NCI pilot intervention program to assist accrual for challenging late phase clinical trials
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr LBA2); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), scientific plenary session (oral);
- Year
- 2014
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CTSU/E3805
Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr LBA1); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), LBA scientific plenary session (oral);
- Year
- 2014
- Research Committee(s)
- Breast and Cancer Survivorship
Randomized comparison of adjuvant treatment with aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC): joint analysis of TEXT and SOFT
- Journal / Conference
- International Society for Quality of Life Research annual meeting (Berlin, Germany, Oct. 15-18, 2014); oral presentation;
- Year
- 2014
- Research Committee(s)
- Cancer Control, Prevention, Screening, and and Surveillance
- Study Number(s)
- S0000, SWOG-9217
Health-related quality of life outcomes in prostate cancer prevention clinical trials
- Journal / Conference
- Urology 84(1):127-131;
- Year
- 2014
- Research Committee(s)
- Cancer Control
- PMID
- PMID24824408
- PMC
- PMC4077907
- Study Number(s)
- SWOG-9217
Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results from the Prostate Cancer Prevention Trial
- Journal / Conference
- Nature Genetics 46(9):994-1000;
- Year
- 2014
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- PMID
- PMID25086665
- PMC
- PMC4191666
- Study Number(s)
- S0000